209960-29-2

Basic information

• Product Name: 2-FLUORO-4-MORPHOLIN-4-YL-PHENYLAMINE
• Synonyms: 2-FLUORO-4-MORPHOLIN-4-YL-PHENYLAMINE;N-(4-AMINO-3-FLUOROPHENYL)MORPHOLINE;2-fluoro-4-(4-morpholinyl)Benzenamine
• CAS NO: 209960-29-2
• Molecular Formula: C₁₀H₁₃FN₂O
• Molecular Weight: 196.2214232
• Mol File: 209960-29-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-FLUORO-4-MORPHOLIN-4-YL-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-FLUORO-4-MORPHOLIN-4-YL-PHENYLAMINE(209960-29-2)
• EPA Substance Registry System: 2-FLUORO-4-MORPHOLIN-4-YL-PHENYLAMINE(209960-29-2)

Safety Data

• Hazardous Substances Data: 209960-29-2(Hazardous Substances Data)

Upstream product

• 110-91-8 morpholine 
• 367-24-8 4-bromo-2-fluoroaniline 
• 446-35-5 2,4-Difluoronitrobenzene 
• 218301-62-3 N-(3-fluoro-4-nitrophenyl)morpholine 

Downstream Products

• 1357481-41-4 1-ethyl-3-(2-fluoro-4-(morpholin-4-yl)phenyl)thiourea 
• 1313809-82-3 C₂₂H₂₂FN₃O₃S 
• 1313809-81-2 C₂₂H₂₂FN₃O₃S 
• 1313809-80-1 C₂₂H₂₂FN₃O₃S 
• 1313809-79-8 C₂₂H₂₂FN₃O₂S 
• 1313809-78-7 3-ethyl-2-(2-fluoro-4-(morpholin-4-yl)phenylimino)thiazolidin-4-one 
• 1313809-94-7 C₂₄H₂₃FN₄O₂S 
• 1313809-93-6 C₂₅H₂₈FN₃O₅S 
• 1313809-92-5 C₂₃H₂₄FN₃O₄S 
• 1313809-91-4 C₂₂H₂₁BrFN₃O₂S 
• 1313809-90-3 C₂₂H₂₁FN₄O₄S 
• 1313809-89-0 C₂₃H₂₄FN₃O₃S 
• 1313809-88-9 C₂₅H₂₈FN₃O₂S 
• 1313809-87-8 C₂₂H₂₁FN₄O₄S 

Relevant articles and documents

SYK INHIBITOR AND USE METHOD THEREFOR

Provided are a Syk inhibitor and a use method therefor, and in particular, disclosed are quinolinone represented by formula (I) or quinazoline derivatives or pharmaceutically acceptable salts thereof, a preparation method, a pharmaceutical composition, and uses in preparing a medicament for treatment of Syk receptor related diseases.

Continuous Synthesis and Purification by Coupling a Multistep Flow Reaction with Centrifugal Partition Chromatography

Continuous-flow multistep synthesis is combined with quasi-continuous final-product purification to produce pure products from crude reaction mixtures. In the nucleophilic aromatic substitution of 2,4-difluoronitrobenzene with morpholine followed by a het

Hydrazine-mediated reduction of nitro and azide functionalities catalyzed by highly active and reusable magnetic iron oxide nanocrystals

Iron oxide (Fe3O4) nanocrystals generated in situ from an inexpensive and readily available iron source catalyze the reduction of nitroarenes to anilines with unparalleled efficiency. The procedure is chemoselective, avoids the use of precious metals, and can be applied under mild reflux conditions (65 or 80 C) or using sealed vessel microwave heating in an elevated temperature regime (150 C). Utilizing microwave conditions, a variety of functionalized anilines have been prepared in nearly quantitative yields within 2-8 min at 150 C, in a procedure also successfully applied to the reduction of aliphatic nitro compounds and azides. The iron oxide nanoparticles are generated in a colloidal form, resulting in homogeneous solutions suitable for continuous flow processing. Selected examples of anilines of industrial importance have been prepared in a continuous regime using this protocol.

Synthesis of 5-benzylidene-3-(3-fluoro-4-yl-morpholin-4-yl-phenylimino)- thiazolidin-4-one derivatives catalyzed by [BmIm]OH and their anti-microbial activity

A series of novel 5-benzylidene-3-(3-fluoro-4-yl-morpholin-4-yl- phenylimino)thiazolidin-4-one derivatives were synthesized using [bmIm]OH as a catalyst and were tested for their antibacterial and antifungal activities. These compounds showed moderate in

NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula (I) or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D may be C(=NH)NH2, which are useful as inhibitors of factor Xa.

Discovery of 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl- N-[2-fluoro-4-[(2′-dimethylaminomethyl)imidazol-1-yl]phenyl] -1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor

Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P1 ligand resulted in compounds with improved selectivity for factor Xa relative to trypsin and plasma kallikrein. Further optimization of the P4 moiety led to compounds with enhanced permeability and reduced protein binding. The SAR and pharmacokinetic profile of this series of compounds is described herein. These efforts culminated in 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2′-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide (11d), a potent, selective, and orally bioavailable inhibitor of factor Xa. On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compound was selected for clinical development as razaxaban (DPC 906, BMS-561389).

NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula (I) or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors of factor Xa.

Guanidine mimics as factor Xa inhibitors

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings D—E represent guanidine mimics, which are useful as inhibitors of factor Xa.

Nitrogen containing heteroaromatics as factor Xa inhibitors

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D may be C(=NH)NH2, which are useful as inhibitors of factor Xa.